DUBLIN, Oct. 3, 2022 /PRNewswire/ — The “Preclinical Medical Device Testing Services Market Size, Share & Trends Analysis Report by Service (Biocompatibility Tests, Chemistry Test, Microbiology & Sterility Testing, Package Validation), by Region, and Segment Forecasts, 2022-2030” report has been added to ResearchAndMarkets.com’s offering.
The global preclinical medical device testing services market share is expected to reach USD 4.9 billion by 2030, according to this report. The rising incidence of diseases has provided manufacturers with different approaches for the formation of medical devices and increasing demand for technologically advanced medical devices are the main factors driving the market growth.
The pace of technological advancement in the healthcare industry has vastly increased in recent years. Medical device technology advancements support simple, painless treatment during disease management. Additionally, advancements in medical device technology help with accurate and quick disease diagnosis results, as well as the affordability of technology-based therapeutic tools for disease treatment. Furthermore, numerous governmental agencies and healthcare institutions support medical research facilities. This funding is primarily intended to promote global health care innovations. The growth of medical device testing in the anticipated period is therefore supported by expanding innovation and technological advancement.
Preclinical testing plays a crucial role in the process of creating new products. Before beginning human testing, most of this testing has been completed and reports should be available. According to ISO-10993, biocompatibility testing results are needed to be included in 510(k) notifications for Class II equipment that has immediate patient contact or contact with the blood supply. This shows that the new device’s risks are “substantially equivalent” to the predicate device’s risks. In order to show the utility of the new device, validate electrical safety, or examine electromagnetic interference, the testing also involves animal and bench studies.
COVID-19 has created an enormous demand for these services. The growth was not significant during the first half, but it became more significant during the second as the industry adopted the new norms at a faster pace amid the pandemic. Numerous projects that were halted because of COVID have been restarted and PPE kits are witnessing an increase in production and testing. During the pandemic, many medical devices in high demand diverted attention from the equipment needed for surgery. The COVID-19 vaccines, ventilators, and pulse oximeters are the main products that witnessed a spike in demand.
Preclinical Medical Device Testing Services Market Report Highlights
The Microbiology & sterility testing segment dominated the market with a revenue share of 34.2% in 2021. It is one of the main tests included in pre-clinical medical device testing These examinations aid in identifying the occurrence of microorganisms in the device
Based on microbiology & sterility test type, sterility test and validation dominated the market with a revenue share of 45.6% in 2021
The chemistry test segment is anticipated to exhibit the fastest CAGR of 9.0%. The test is conducted in order to categorize, recognize, and understand the chemicals used in the production of medical devices
Asia Pacific led the global market in 2021 and is projected to witness the fastest CAGR of 9.0% during the forecast years due to the low cost of outsourcing medical device testing services
Key Topics Covered:
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Preclinical Medical Device Testing Services Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.1.1. Complexity in Product design
3.3.1.2. Strict Approval Norms
3.3.1.3. Increase in number of small medical device lacking in-house testing capabilities
3.3.2. Market restraint analysis
3.3.2.1. Legal and Regulatory Issues
3.3.3. Penetration & Growth Prospect Mapping
3.3.4. COVID Impact Analysis
3.3.5. Major Deals and Strategic Alliances Analysis
3.3.6. Industry Analysis – Porter’s Five Forces Analysis
3.3.7. Pestle Analysis
Chapter 4. Preclinical Medical Device Testing Services Market: Services Segment Analysis
4.1. Preclinical Medical Device Testing Services Market: Definition & Scope
4.2. Preclinical Medical Device Testing Services Market: Services Market Share Analysis, 2021 & 2030
4.3. Biocompatibility Tests
4.3.1. Biocompatibility Tests Market, 2018 – 2030 (USD Million)
4.4. Chemistry Test
4.4.1. Chemistry Test Market, 2018 – 2030 (USD Million)
4.5. Microbiology & Sterility Testing
4.5.1. Microbiology & Sterility Testing Market, 2018 – 2030 (USD Million)
4.5.2. Bioburden Determination
4.5.2.1. Bioburden Determination Market, 2018 – 2030 (USD Million)
4.5.3. Pyrogen & Endotoxin Testing
4.5.3.1. Pyrogen & Endotoxin Testing Market, 2018 – 2030 (USD Million)
4.5.4. Sterility Test and Validation
4.5.4.1. Sterility Test and Validation Market, 2018 – 2030 (USD Million)
4.5.4.2. Ethylene Oxide (EO) gas sterilization
4.5.4.2.1. Ethylene Oxide (EO) gas sterilization Market, 2018 – 2030 (USD Million)
4.5.4.3. Gamma-irradiation
4.5.4.3.1. Gamma-irradiation Market, 2018 – 2030 (USD Million)
4.5.4.4. E-beam sterilization
4.5.4.4.1. E-beam Sterilization Market, 2018 – 2030 (USD Million)
4.5.4.5. X-ray sterilization
4.5.4.5.1. X-ray sterilization Market, 2018 – 2030 (USD Million)
4.5.5. Antimicrobial activity testing
4.5.5.1. Antimicrobial activity testing Market, 2018 – 2030 (USD Million)
4.5.6. Others
4.5.6.1. Others Market, 2018 – 2030 (USD Million)
4.6. Packaging Validation
4.6.1. Packaging Validation Market, 2018 – 2030 (USD Million)
Chapter 5. Preclinical Medical Device Testing Services Market: Regional Analysis
Chapter 6. Competitive Landscape
6.1. Company Profiles
6.1.1. SGS SA,
6.1.1.1. Company overview
6.1.1.2. Financial performance
6.1.1.3. Service benchmarking
6.1.1.4. Strategic initiatives
6.1.2. LabCorp
6.1.2.1. Company overview
6.1.2.2. Financial performance
6.1.2.3. Service benchmarking
6.1.2.4. Strategic initiatives
6.1.3. Eurofins Scientific
6.1.3.1. Company overview
6.1.3.2. Financial performance
6.1.3.3. Service benchmarking
6.1.3.4. Strategic initiatives
6.1.4. Pace Analytical Services Llc
6.1.4.1. Company overview
6.1.4.2. Financial performance
6.1.4.3. Service benchmarking
6.1.4.4. Strategic initiatives
6.1.5. Intertek Group PLC
6.1.5.1. Company overview
6.1.5.2. Financial performance
6.1.5.3. Service benchmarking
6.1.5.4. Strategic initiatives
6.1.6. Wuxi AppTec
6.1.6.1. Company overview
6.1.6.2. Financial performance
6.1.6.3. Service benchmarking
6.1.6.4. Strategic initiatives
6.1.7. Tuv Sud Ag
6.1.7.1. Company overview
6.1.7.2. Financial performance
6.1.7.3. Service benchmarking
6.1.7.4. Strategic initiatives
6.1.8. Sterigenics International LLC
6.1.8.1. Company overview
6.1.8.2. Financial performance
6.1.8.3. Service benchmarking
6.1.8.4. Strategic initiatives
6.1.9. Nelson Labs
6.1.9.1. Company overview
6.1.9.2. Financial performance
6.1.9.3. Service benchmarking
6.1.9.4. Strategic initiatives
6.1.10. North American Science Associates, Inc.
6.1.10.1. Company overview
6.1.10.2. Financial performance
6.1.10.3. Service benchmarking
6.1.10.4. Strategic initiatives
6.1.11. Charles River Laboratories International, Inc.
6.1.11.1. Company overview
6.1.11.2. Financial performance
6.1.11.3. Service benchmarking
6.1.11.4. Strategic initiatives
For more information about this report visit https://www.researchandmarkets.com/r/p4hsjw
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/the-worldwide-preclinical-medical-device-testing-services-industry-is-expected-to-reach-4-9-billion-by-2030–301638714.html
SOURCE Research and Markets
DEEP DIVE When the stock market has jumped two days in a row, as it has now, it is easy to become complacent. But the Federal Reserve isn’t finished raising interest rates, and recession talk abounds.
Elon Musk's U-turn on buying Twitter Inc could not have come at a worse time for the banks funding a large portion of the $44 billion deal and they could be facing significant losses. While Musk will provide much of $44 billion by selling down his stake in electric vehicle maker Tesla Inc and by leaning on equity financing from large investors, major banks have committed to provide $12.5 billion. They include Morgan Stanley, Bank of America Corp and Barclays Plc.
As Nio expands outside of China, investors are paying close attention to how it may perform globally.
You can hold on to Series I bonds for 30 years, but if you jumped in when the interest rate skyrocketed to 9.62%, you might be looking for an off-ramp well before then. The total return on I-bonds is made up of two parts — a fixed rate that’s set at the time of purchase and an inflation-adjusted rate that resets every six months, in November and May. The fixed rate has been 0% since May 2020. Looking at numbers already published, David Enna, founder of TipsWatch.com, a website that tracks inflation-protected securities, predicts the variable inflation-adjusted portion of the I-bonds formula will be around 6.3%, and likely fall to 3.5% eventually.
The time to buy Boeing is now, one analyst argues.
Shares of some growth stocks were spiking today as the broader market indices jumped. As a result, investors returned to some technology stocks today, helping to lift Shopify (NYSE: SHOP) by 13.5%, PayPal Holdings (NASDAQ: PYPL) by 5.2%, and Appian (NASDAQ: APPN) by 7.3% as of 10:30 a.m. ET.
Top trending stocks in after hours trading on Tuesday, October 4, 2022.
The debt crisis is here, Nouriel Roubini says. Expect central banks to wimp out in their fight against inflation as financial distress deepens
Crossmark Global Investments Chief Market Strategist Victoria Fernandez and KeyAdvisors Group Owner Eddie Ghabour sit down with Yahoo Finance Live to talk about the outlook during this bear market and the Fed's position amid inflationary and labor market pressures.
In this article, we discuss 10 American stocks that will benefit from the new Cold War. If you want to see more stocks in this selection, check out 5 American Stocks That Will Benefit from the New Cold War. A March 2022 survey indicated that more than 6 in 10 American adults believe that the […]
In this article, we discuss 11 best American dividend stocks to buy now. You can skip our detailed analysis of dividend stocks and their historical performance, and go directly to read 5 Best American Dividend Stocks to Buy Now. Due to the rising inflation and continuous interest rate hikes this year, dividend stocks are in […]
The rally attempt continued as Treasury yields and the dollar fell. Here are 5 stocks near early buy points. Twitter surged as Tesla's Elon Musk will go ahead with his $44 billion deal.
Archer-Daniels Midland, Chevron, Exxon Mobil, General Dynamics, and Genuine Parts made our cut for the safest dividends of the S&P 500 Dividend Aristocrats.
(Bloomberg) — US stocks may resume their slump as they have only just begun to price in a recession, according to Citigroup Inc.’s quant strategists. The market has turned “decidedly defensive again,” the strategists including Hong Li wrote in a note Tuesday. Recent synchronized moves suggest “equity investors are paying closer attention to the increased credit risk,” they wrote.To make matters worse, the upcoming earnings season may do little to help sentiment given that stock correlations hav
Elon Musk has a new plan for Twitter Inc. after giving up a legal battle and agreeing to pay $44 billion for the company Tuesday.
What happened Shares of Sorrento Therapeutics (NASDAQ: SRNE), a biotech company that specializes in oncology and pain therapies, dropped 23.4% in September, according to data from S&P Global Intelligence.
To get a sense of who is truly in control of Senti Biosciences, Inc. ( NASDAQ:SNTI ), it is important to understand the…
In this article, we discuss the 11 best cheap stocks to buy, according to billionaire Dalio. If you want to see more stocks in his portfolio, go to the 5 Best Cheap Stocks To Buy According To Billionaire Dalio. In a LinkedIn post published on September 15, billionaire hedge fund manager Ray Dalio shared his […]
Twitter shares jumped more than 22% to end at $52.00 on Tuesday after a securities filing showed Musk intends to go ahead with his April offer of $44 billion to take the company private, signaling an end to a legal battle that could have forced Musk to pay up. The estimated profit for Icahn Enterprises LP could exceed $250 million, it added.
Have an issue with your financial adviser or have questions about hiring a new one? Email picks@marketwatch.com.
